Cargando…
Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer
Background. Assessment of DNA methylation of specific genes is one approach to the diagnosis of cancer worldwide. Early stage detection is necessary to reduce the mortality rate of cancers, including those occurring in the stomach. For this purpose, tumor cells in circulating blood offer promising c...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906662/ https://www.ncbi.nlm.nih.gov/pubmed/27330867 http://dx.doi.org/10.7717/peerj.2112 |
_version_ | 1782437448277557248 |
---|---|
author | Pimson, Charinya Ekalaksananan, Tipaya Pientong, Chamsai Promthet, Supannee Putthanachote, Nuntiput Suwanrungruang, Krittika Wiangnon, Surapon |
author_facet | Pimson, Charinya Ekalaksananan, Tipaya Pientong, Chamsai Promthet, Supannee Putthanachote, Nuntiput Suwanrungruang, Krittika Wiangnon, Surapon |
author_sort | Pimson, Charinya |
collection | PubMed |
description | Background. Assessment of DNA methylation of specific genes is one approach to the diagnosis of cancer worldwide. Early stage detection is necessary to reduce the mortality rate of cancers, including those occurring in the stomach. For this purpose, tumor cells in circulating blood offer promising candidates for non-invasive diagnosis. Transcriptional inactivation of tumor suppressor genes, like PCDH10 and RASSF1A, by methylation is associated with progression of gastric cancer, and such methylation can therefore be utilized as a biomarker. Methods. The present research was conducted to evaluate DNA methylation in these two genes using blood samples of gastric cancer cases. Clinicopathological data were also analyzed and cumulative survival rates generated for comparison. Results. High frequencies of PCDH10 and RASSF1A methylations in the gastric cancer group were noted (94.1% and 83.2%, respectively, as compared to 2.97% and 5.45% in 202 matched controls). Most patients (53.4%) were in severe stage of the disease, with a median survival time of 8.4 months after diagnosis. Likewise, the patients with metastases, or RASSF1A and PCDH10 methylations, had median survival times of 7.3, 7.8, and 8.4 months, respectively. A Kaplan–Meier analysis showed that cumulative survival was significantly lower in those cases positive for methylation of RASSF1A than in their negative counterparts. Similarly, whereas almost 100% of patients positive for PCDH10 methylation had died after five years, none of the negative cases died over this period. Notably, the methylations of RASSF1A and PCDH10 were found to be higher in the late-stage patients and were also significantly correlated with metastasis and histology. Conclusions. PCDH10 and RASSF1A methylations in blood samples can serve as potential non-invasive diagnostic indicators in blood for gastric cancer. In addition to RASSF1A methylation, tumor stage proved to be a major prognostic factor in terms of survival rates. |
format | Online Article Text |
id | pubmed-4906662 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | PeerJ Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-49066622016-06-17 Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer Pimson, Charinya Ekalaksananan, Tipaya Pientong, Chamsai Promthet, Supannee Putthanachote, Nuntiput Suwanrungruang, Krittika Wiangnon, Surapon PeerJ Molecular Biology Background. Assessment of DNA methylation of specific genes is one approach to the diagnosis of cancer worldwide. Early stage detection is necessary to reduce the mortality rate of cancers, including those occurring in the stomach. For this purpose, tumor cells in circulating blood offer promising candidates for non-invasive diagnosis. Transcriptional inactivation of tumor suppressor genes, like PCDH10 and RASSF1A, by methylation is associated with progression of gastric cancer, and such methylation can therefore be utilized as a biomarker. Methods. The present research was conducted to evaluate DNA methylation in these two genes using blood samples of gastric cancer cases. Clinicopathological data were also analyzed and cumulative survival rates generated for comparison. Results. High frequencies of PCDH10 and RASSF1A methylations in the gastric cancer group were noted (94.1% and 83.2%, respectively, as compared to 2.97% and 5.45% in 202 matched controls). Most patients (53.4%) were in severe stage of the disease, with a median survival time of 8.4 months after diagnosis. Likewise, the patients with metastases, or RASSF1A and PCDH10 methylations, had median survival times of 7.3, 7.8, and 8.4 months, respectively. A Kaplan–Meier analysis showed that cumulative survival was significantly lower in those cases positive for methylation of RASSF1A than in their negative counterparts. Similarly, whereas almost 100% of patients positive for PCDH10 methylation had died after five years, none of the negative cases died over this period. Notably, the methylations of RASSF1A and PCDH10 were found to be higher in the late-stage patients and were also significantly correlated with metastasis and histology. Conclusions. PCDH10 and RASSF1A methylations in blood samples can serve as potential non-invasive diagnostic indicators in blood for gastric cancer. In addition to RASSF1A methylation, tumor stage proved to be a major prognostic factor in terms of survival rates. PeerJ Inc. 2016-06-09 /pmc/articles/PMC4906662/ /pubmed/27330867 http://dx.doi.org/10.7717/peerj.2112 Text en ©2016 Pimson et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
spellingShingle | Molecular Biology Pimson, Charinya Ekalaksananan, Tipaya Pientong, Chamsai Promthet, Supannee Putthanachote, Nuntiput Suwanrungruang, Krittika Wiangnon, Surapon Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer |
title | Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer |
title_full | Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer |
title_fullStr | Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer |
title_full_unstemmed | Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer |
title_short | Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer |
title_sort | aberrant methylation of pcdh10 and rassf1a genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer |
topic | Molecular Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906662/ https://www.ncbi.nlm.nih.gov/pubmed/27330867 http://dx.doi.org/10.7717/peerj.2112 |
work_keys_str_mv | AT pimsoncharinya aberrantmethylationofpcdh10andrassf1agenesinbloodsamplesfornoninvasivediagnosisandprognosticassessmentofgastriccancer AT ekalaksananantipaya aberrantmethylationofpcdh10andrassf1agenesinbloodsamplesfornoninvasivediagnosisandprognosticassessmentofgastriccancer AT pientongchamsai aberrantmethylationofpcdh10andrassf1agenesinbloodsamplesfornoninvasivediagnosisandprognosticassessmentofgastriccancer AT promthetsupannee aberrantmethylationofpcdh10andrassf1agenesinbloodsamplesfornoninvasivediagnosisandprognosticassessmentofgastriccancer AT putthanachotenuntiput aberrantmethylationofpcdh10andrassf1agenesinbloodsamplesfornoninvasivediagnosisandprognosticassessmentofgastriccancer AT suwanrungruangkrittika aberrantmethylationofpcdh10andrassf1agenesinbloodsamplesfornoninvasivediagnosisandprognosticassessmentofgastriccancer AT wiangnonsurapon aberrantmethylationofpcdh10andrassf1agenesinbloodsamplesfornoninvasivediagnosisandprognosticassessmentofgastriccancer |